• FY25 revenue on track to be a record year, up 14% YTD
• U.S. sales growth accelerating with HCPCS insurance code reimbursement
• NeuroStrip commercialisation progressing with updated hardware in trials

Control Bionics Limited (ASX:CBL), an Australian leader in Electromyography (EMG) medical device technology, is pleased to provide a trading update ahead of the close of the financial year ending 30 June 2025. FY25 is on track to be the strongest revenue year in the Company's history, with year-to-date unaudited revenue to 31 May 2025 up 14% to ~$5.4m compared to the prior corresponding period. This has been driven by strong performance in the United States, where revenue growth has been significantly bolstered by the benefits of the new Healthcare Common Procedure Coding System (HCPCS) insurance code, and growth in Australia, where more consistent approvals from the National Disability Insurance Scheme (NDIS) have underpinned a strong year for revenue growth. The Company remains focused on executing its strategy to diversify revenues beyond assistive communication into high-growth areas such as sports performance, rehabilitation, and health diagnostics. The latest version of the NeuroStrip hardware is being trialled across the U.S., Australia and Japan, delivering an extraordinarily efficacious outcome for users. The updated app supports instant data review, data labelling, usage logging, and real-time analytics--key features to support its rollout as a SaaS product. These enhancements are expected to unlock new recurring revenue streams and provide valuable insight into product usage and performance. The NeuroBounce program, powered by Control Bionics' NeuroStrip, continues to gain commercial traction as a compelling application of the company's EMG technology in the sports performance market, with successful trials in both the U.S. and Australia.

FY25 revenue is on track to be a record year, with YTD unaudited revenue to 31 May 2025 up 14% to ~$5.4m compared to the prior corresponding period.

The Company remains focused on executing its strategy to diversify revenues beyond assistive communication into high-growth areas such as sports performance, rehabilitation, and health diagnostics. The latest version of the NeuroStrip hardware is being trialled across the U.S., Australia and Japan, and the updated app is expected to unlock new recurring revenue streams and provide valuable insight into product usage and performance. The NeuroBounce program, powered by the NeuroStrip, continues to gain commercial traction in the sports performance market.